Methods for Handling Unobserved Covariates in a Bayesian Update of a Cost-effectiveness Model. by Thorpe, Benjamin et al.
Methods for handling unobserved covariates in a
Bayesian update of a cost-effectiveness model
Benjamin Thorpe, PhD∗, Orlagh Carroll, BSc†, Linda Sharples, PhD‡
September 11, 2017
Abstract
Health economic decision models often involve a wide-ranging and compli-
cated synthesis of evidence from a number of sources, making design and
implementation of such models resource-heavy. When new data become
available and reassessment of treatment recommendations is warranted, it
may be more efficient to perform a Bayesian update of an existing model
than to construct a new model. If the existing model depends on many,
possibly correlated, covariates then an update may produce biased es-
timates of model parameters if some of these covariates are completely
absent from the new data. Motivated by the need to update a cost-
effectiveness analysis comparing diagnostic strategies for coronary heart
disease, this study develops methods to overcome this obstacle by either
introducing additional data or using results from previous studies. We
outline a framework to handle unobserved covariates, and use our moti-
vating example to illustrate both the flexibility of the proposed methods
and some potential difficulties in applying them.
Introduction
Long-term health economic decision models have complicated mathematical
structures, with model parameters informed by a range of data sources, in-
cluding mortality rates, clinical outcomes, incidence of clinical events, costs and
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utilities.1 Given the resources involved in the design and implementation of
these models, when reassessment of the treatment decisions is required due to
accrual of new data, conducting a Bayesian update of the model parameters
may be more efficient than designing a new model.
Many parameters within decision models are conditional on patient covari-
ates, representing demographics, clinical histories and treatments. These covari-
ates might be necessary to allow for changes in patients’ characteristics as they
transition between health states within the model, or they might be used to
restrict the analysis to a specific patient population. If, for example, a decision
model depends on prediction equations for risk of clinical events then the coeffi-
cients of the regression equations will have been adjusted for the other variables
involved, and this should be reflected in the analysis.2 Any Bayesian updating
of these equations must therefore update all coefficients simultaneously in order
to accommodate correlations between coefficients.3
Intermittently missing data are common in updates that require data on
many different covariates. They may be handled by treating missing values
as uncertain quantities and assigning distributions to them.4,5 A potentially
greater obstacle is the complete absence of some necessary variables from the
accrued data. Commonly-used missing data methods cannot be applied because
they require at least some observations for each variable.
Our motivating example is an update of an existing cost-effectiveness study
and its probabilistic sensitivity analysis (PSA). Assessment of decision uncer-
tainty through PSA, by assigning distributions to uncertain model parameters
and propagating that uncertainty through the model,6 is a requirement of deci-
sion makers such as The National Institute for Health and Care Excellence.7 It
is also considered a hallmark of good practice by the ISPOR-SMDM Modeling
Good Research Practices Task Force, who recommend incorporating all avail-
able data through evidence synthesis techniques.2 In our example, individual
patient data (IPD) had become available, which we hoped to incorporate in the
PSA by performing a Bayesian update of the parameter distributions. However,
a necessary covariate had not been observed.
Ignoring new data would not be good practice as it would ignore current,
available and relevant evidence. Proceeding with an inappropriate synthesis,
ignoring important correlations between observed and unobserved covariates,
could produce biased results. Our goal in this paper is therefore to present sim-
ple methods to overcome the problem of unobserved covariates in a Bayesian
update. These are similar to methods used for intermittently missing data,
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with the important difference that distributions assigned to unobserved covari-
ates must be informed by external evidence, such as estimated distributions
from published research or IPD from another study.
Full details of our motivating example are given in the following section. In
the subsequent section, we propose methods to handle unobserved covariates
in a number of general situations. We apply these methods to our example,
illustrating their flexibility and highlighting potential difficulties. In the final
section, we discuss their advantages and limitations. Although we focus on up-
dating the inputs of a cost-effectiveness model, rather than the model structure,
our motivating example demonstrates how the structure and assumptions of the
model are important considerations in applying these methods.
Motivating example
Coronary heart disease (CHD) is the stenosis (narrowing) of coronary arteries.
The extent of stenosis, and thus a patient’s need for revascularisation, can be
assessed through diagnostic imaging techniques, including cardiovascular mag-
netic resonance imaging (MRI), single-photon emission computed tomography
(SPECT) and X-ray coronary angiography (CA).
The CE-MARC study8,9 compared the accuracy of SPECT and MRI in the
diagnosis of CHD with significant stenosis (i.e. stenosis sufficient for revascular-
isation). Eligible patients were referrals to cardiologists with suspected angina.
Participants were scheduled to undergo both MRI and SPECT. Each partici-
pant was also scheduled to have the true extent of their stenosis classified by
CA (Table 1), which was assumed to be the gold standard (perfect sensitivity
and specificity).
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CHD with signifi-
cant stenosis
At least 70% stenosis of a first order coronary artery
at least 2mm in diameter, or left main stem stenosis
of at least 50%.
CHD without sig-
nificant stenosis
No significant stenosis, but at least 10% stenosis
of at least one first order coronary artery at least
2mm in diameter, or at least 10% stenosis of the
left main stem.
No CHD Less than 10% stenosis of all first order coronary
arteries at least 2mm in diameter, and less than
10% stenosis of the left main stem.
Table 1: Classification of CHD by angiography. The CE-MARC study
considered diagnosis of CHD with significant stenosis. Further classification of
patients without significant stenosis into those with and without CHD was
introduced later, in the cost-effectiveness study.
Alongside the CE-MARC trial analysis, a cost-effectiveness study was un-
dertaken.10 This study considered the subset of the CE-MARC population that
was eligible for exercise tolerance testing (ETT) and had not previously un-
dergone revascularisation. Eight diagnostic strategies were compared, including
combinations of ETT, SPECT, MRI and CA. For example, a patient might
undergo an MRI-CA sequence. A patient testing negative in MRI would not
undergo the subsequent CA or revascularisation. A patient testing positive in
MRI would then undergo CA and thus be correctly diagnosed and revascularised
if necessary.
Using a decision analytic model (Figure 1), expected costs and quality-
adjusted life years (QALYs) were estimated for each strategy over a 50-year
time horizon. Each strategy would allocate patients to one of four states: true
positive (TP), true negative (TN), false negative (FN), or death (caused by CA).
This was modelled using decision trees. Positive test sequences would always
end with CA and therefore false positives were not considered possible. For
patients with and without CHD, separate Markov models were used to model
pathways following testing.
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Figure 1: The cost-effectiveness model used in CE-MARC, illustrated for the
MRI-CA testing stratgy. Health states are represented by ellipses, events by
rectangles, and transitions by arrows. Only patients with significant stenosis,
confirmed by CA, would undergo revascularisation and thus enter the TP
state. Transitions from FN to TP would require identification via CA, followed
by revascularisation.
For patients with CHD, transitions involving CV events (defined as myocar-
dial infarction, cardiac arrest or cardiovascular death) were explicitly modelled,
with transition probabilities depending on the incidence rate and mortality of
these events. Before long-term follow-up data from CE-MARC became avail-
able, the required estimates were taken from published results of the EUROPA
study.11,12
For example, a patient’s time to first CV event, which we denote here by y,
was assumed to be exponentially distributed, with event rate λ depending on
17 patient-level covariates in a proportional hazards model:
y | x, β ∼ Exp(λ), λ = exp (β0 + β1x1 + . . .+ β17x17) ,
where β = (β0, . . . , β17) denotes a vector of parameters and x = (x1, . . . , x17)
includes baseline characteristics such as previous myocardial infarction and pre-
vious revascularisation. In the CE-MARC cost-effectiveness study, β was as-
signed a multivariate normal distribution, with mean and covariance matrix as
estimated in EUROPA.
However, EUROPA recruited patients with evidence of CHD, such as previ-
ous myocardial infarction (64% of patients recruited), previous revascularisation
(55%) or angiographic evidence of significant stenosis (61%), and a few with
only a positive nuclear stress test (5%). Therefore estimates from EUROPA
might require adjustment to accurately reflect the population of the CE-MARC
cost-effectiveness analysis. In particular, patients with CHD in the TN state of
Figure 1 do not have significant stenosis and therefore do not necessarily meet
the main inclusion criteria of EUROPA. Despite this, the original CE-MARC
cost-effectiveness model used the same estimated incidence rates from EUROPA
in all three initial states (TN, FN and TP). This required an implicit assumption
that, in patients with CHD, time to first CV event is independent of the ex-
tent of stenosis, given the other patient characteristics adjusted for in EUROPA.
Annual follow-ups for cardiac events were planned for each CE-MARC pa-
tient over a period of at least five years.13 With these data, the cost-effectiveness
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analysis could be updated by obtaining posterior distributions for model param-
eters related to the rate of CV events. Furthermore, information on extent of
stenosis, from the detailed angiography results of each patient, could be used
to investigate the assumption described above. Our goal was therefore to use
the newly available IPD both to update model parameters and to adjust for an
additional variable indicating severity of stenosis. CV events are associated with
high risk of death, high treatment costs and reduced quality of life, and therefore
such an update could have a significant impact on the cost-effectiveness results.
A major obstacle to this update was the complete absence of a necessary
variable, symptomatic angina, from the CE-MARC data. This was a covariate
in the proportional hazards model estimated in EUROPA, and was also used
to specify scenario analyses in the CE-MARC cost-effectiveness study. It was
therefore important that we did not ignore this variable in our update.
Methods
General problem
Suppose we wish to update model parameter estimates from an initial study
(Study 1) using data from a new study (Study 2). We assume that we only
have summary data from Study 1, but that IPD are available from Study 2.
We are interested in the situation where a conditional probability distribu-
tion p(y | x, β) has been estimated in Study 1; this represents the distribution of
an outcome y (e.g. time to CV event) conditional on covariates x and regression
coefficients β. A joint distribution p(β) describes the current uncertainty in the
parameter vector β, prior to observing data from Study 2.
We denote by y(k)i and x(k)i the values of the outcome variable y and covari-
ate vector x for the i-the individual of Study k, where i = 1, 2, . . . , n(k). Suppose
that the vector of covariates can be decomposed as x = (x′, x′′), such that the
vector x′′(2)i was observed for each individual in Study 2 but the vector x
′
(2)i was
not. Our general problem reduces to estimating the posterior distribution of β
conditional on all n(2) observations (y(2)i, x
′′
(2)i) from Study 2.
Updating when all covariates are available in Study 2
Bayesian updating is most straightforward when we observe all variables (y, x)
for each individual in Study 2. We only need to specify the prior p(β) from
Study 1 and the likelihood p(y | x, β) in order to obtain the posterior distri-
bution of β, conditional on all n(2) observations (y(2)i, x(2)i), via Bayes’ theorem.
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The necessary relationships between observed data and model parameters
can be specified in the directed acyclic graph (DAG)14 shown in Figure 2. We
have the observed data y(2)i and x(2)i from Study 2 (rectangular nodes), and an
uncertain parameter vector β (circular). Arrows into y(2)i show its dependence
on x(2)i and β through the specified likelihood. The plate (dashed rectangle)
indicates that the same relationship holds for all i = 1, 2, . . . , n(2).
Figure 2: DAG for updating p(β) when all covariates are observed in Study 2.
In many Bayesian analyses, particularly those involving many parameters,
mathematical derivations of posterior distibutions are unavailable. Markov
Chain Monte Carlo (MCMC) methods, such as Gibbs sampling, are therefore
used to sample from the posterior distribution of the model parameters.15
Unobserved covariates in Study 2
Suppose that a subset x′ of the covariates x = (x′, x′′) was not observed
in Study 2, so that the observed data in Study 2 comprises (y(2)i, x
′′
(2)i) for
i = 1, 2, . . . , n(2). Since our likelihood is p(y | x′, x′′, β), without data on x′(2)i
we cannot directly use Bayes’ theorem to obtain the posterior distribution of β.
However, if we can assign a distribution to each x′(2)i, conditional on x
′′
(2)i, we
might proceed by treating each x′(2)i as an uncertain parameter.
We need to identify a distribution, p(x′ | x′′, γ) (with parameter vector γ),
relating the unobserved covariates and the observed covariates. For example,
this distribution might have been estimated in a previous study (Study 3). This
leads to the model in Figure 3.
Figure 3: DAG for updating β when there are unobserved covariates x′ in
Study 2 imputed from observed covariates x′′.
When performed via Gibbs sampling, this method of handling unobserved
covariates is analogous to multiple imputation of missing data. All uncertain pa-
rameters, including each component of the vector x′(2)i, are sampled sequentially
from their full conditional distributions (conditional on all other parameters and
the observed data). In each iteration, values of β are therefore sampled condi-
tional on the previously sampled values of x′(2)i.
Properties of this method are also comparable to the usual recommenda-
tions16 for imputation of missing covariates: each component of x′(2)i is drawn
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from a distribution that conditions on all other variables in the model of interest
(including y(2)i) and additional parameter uncertainty is accounted for in the
prior p(γ).
We have not assumed that we have IPD from the distribution of x′, only that
the parameters and nature of their distribution are available from an existing
study. However, if we had IPD from Study 3, we could estimate p(x′ | x′′, γ)
ourselves and (for example) determine p(γ) using asymptotic properties of max-
imum likelihood estimators.
Additional assumptions required for the case of unobserved
covariates in Study 3
Where the number of covariates in x′′ is large, it is possible, even likely, that
some of these will not have been observed in Study 3 (or simply not included
when estimating the distribution of x′). Thus the covariate vector x can be
decomposed into x = (x′, x′′, x′′′), where x′ was observed in Study 1 and Study
3 only, x′′ was observed in all three studies, and x′′′ was observed in Study 1
and Study 2 only.
If we have p(x′ | x′′, γ) from Study 3, we can use this to update β, provided
that we can make an additional assumption that x′ is independent of x′′′ given
x′′ and γ; we denote this by x′ ⊥⊥ x′′′ | (x′′, γ). Figure 4 shows the DAG
corresponding to these assumptions.
Figure 4: DAG for updating β when there are unobserved covariates x′ in
Study 2 imputed from a subset x′′ of the observed covariates.
Additional covariates in Study 3
Another potential difficulty is that the distribution estimated for x′ in Study
3 might include additional, unwanted covariates. Suppose that we have an
estimated distribution p(x′ | x′′, z, γ) from Study 3, where z is a vector of
covariates not in x. Suppose also that we do not have IPD from Study 3. Our
update can still be performed if z was observed in Study 2 and if we can assume
both x′ ⊥⊥ x′′′ | (x′′, z, γ) and y ⊥⊥ z | (x, β). See Figure 5.
Figure 5: DAG for updating β when there are unobserved covariates x′ in
Study 2 imputed from observed covariates x′′ and additional observed
covariates z.
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Additional covariates can sometimes be used to our advantage. For example,
if the IPD from Study 3 are available, we might incorporate additional covariates
to strengthen confidence in our independence assumptions. We would choose
variables z that are not in x and then estimate p(x′ | x′′, z, γ) and p(γ). For
example, we might choose z such that an assumption x′ ⊥⊥ x′′′ | (x′′, z, γ) is
more plausible than an assumption x′ ⊥⊥ x′′′ | (x′′, γ). This is analogous to in-
clusion of auxiliary variables in a multiple imputation model to make a ‘missing
at random’ assumption more plausible.
This two-stage approach (estimation of p(x′ | x′′, z, γ), followed by updating
β) could be performed in a single step by including the Study 3 data directly
in our Bayesian model, as illustrated in Figure 6.
Figure 6: DAG for updating β and γ simultaneously using data sets from both
Study 2 and Study 3.
Handling unobserved covariates in multiple studies in a
one-stage analysis
If Study 2 and Study 3 do not provide covariates z for which assumptions
x′ ⊥⊥ x′′′ | (x′′, z, γ) and y ⊥⊥ z | (x, β) are plausible then the model in Figure 6
is not tenable. One option is to use the covariates x′′, available in both Study 2
and Study 3, to impute x′′′ in Study 3, as illustrated in Figure 7. This requires
additional distributional assumptions: p(x′′′ | x′′, θ) with parameter vector θ,
relating observed and unobserved covariates, and a prior p(θ). An assumption
x′ ⊥⊥ x′′′ | (x′′, γ) is not required.
Figure 7: DAG for updating β, using data sets from both Study 2 and Study
3, with imputation of unobserved covariates x′ in Study 2 and x′′′ in Study 3.
The models presented so far apply to a broad range of problems and can be
extended to more specific problems after careful specification of additional dis-
tributions and conditional independence assumptions. For example, the model
in Figure 7 could be extended to include auxiliary variables z in the imputation
of x′ and x′′′.
Application
We now describe the application of the proposed methods to our example of
updating the CE-MARC cost-effectiveness analysis. We focus on updating pa-
rameters related to the rate of CV events for patients with CHD in the three
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initial states (FN, TN and TP) of Figure 1.
Recall that the distribution of time to first CV event, y, was estimated
in the EUROPA study using a parametric proportional hazards model with
17 baseline characteristics as covariates. In the CE-MARC cost-effectiveness
model, the population consisted of patients with no history of revascularisation,
so the likelihood and prior information from EUROPA reduced to:
y | x, β ∼ Exp(λ), λ = exp
(
β0 +
∑16
i=1 βixi
)
, β = (β0, . . . , β16) ∼ N17(µ,Σ),
where λ now denotes the CV event rate for a patient with baseline characteris-
tics x = (x1, . . . , x16) who has not undergone revascularisation prior to testing.
Given the EUROPA eligibility criteria, these distributions were considered to be
directly applicable to patients with significant stenosis, and therefore to tran-
sitions from the FN and TP states. However, as noted, their application to
transitions from the TN state required an assumption that CV event rate does
not depend on the extent of stenosis, given its existence and given the values
of other covariates in the model. This assumption was not made on the basis
of any established evidence. For CE-MARC participants, we had data on both
time to first CV event (from follow-up) and stenosis (from angiography), and
could therefore investigate the validity of this assumption.
We extended the proportional hazards model to include x17, an indicator for
insignificant stenosis, and β17, an additional regression coefficient:
y | x, β ∼ Exp(λ), λ = exp
(
β0 +
∑17
i=1 βixi
)
,
where x = (x1, . . . , x17) and β = (β0, . . . , β17). The additional hazard ratio
(eβ17) would apply to patients in the TN state, since these patients would have
only insignificant stenosis (x17 = 1). Patients in the TP or FN states would
all have significant stenosis at the time of testing (x17 = 0), and therefore the
model for y would reduce to the one specified in EUROPA.
We took the prior (β0, . . . , β16) ∼ N17(µ,Σ), as estimated in EUROPA. We
took a weakly informative, independent normal prior for β17, with mean 0 and
standard deviation 0.97, so that eβ17 would have median 1 and around 50%
probability of lying between 1/2 and 2. Our primary goal was therefore to up-
date p(β), the multivariate normal distribution taken as the prior of β, using
IPD from CE-MARC.
We note that other cost-effectiveness analyses, including some with the same
decision model structure as CE-MARC,17 have similarly allowed event rates to
differ between states by multiplying them by appropriate factors. These factors
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are often taken from previously published studies, without any adjustment.
Possible correlations with other parameters in the decision model are therefore
overlooked, and potentially related parameters are varied independently in PSA.
A strength of our Bayesian approach is that, by using IPD and specifying only
weak prior information for the additional parameter, these potential correlations
are accommodated in the posterior.
Data
CE-MARC recruited 752 patients, of whom 296 were eligible for ETT, had not
previously undergone revascularisation, and had angiographic evidence of CHD
with either significant or insignificant stenosis. To avoid overcomplicating pre-
sentation of our methods, we excluded a further 24 patients with intermittently
missing data in the observed covariates. We therefore present a complete case
analysis using IPD from 272 CE-MARC patients.
Symptomatic angina, defined in EUROPA as a Canadian Cardiovascular So-
ciety (CCS) grading of II or higher (chest pain during ordinary physical activi-
ties), was not recorded in CE-MARC. Because of this, straightforward updating
(Figure 2) of p(β) was not possible.
We therefore introduced a third study into our analysis, CECaT,18 from
which had access to a subset of the baseline data, including CCS grading. CE-
CaT compared diagnostic strategies for CHD and recruited 898 patients who
were eligible for ETT and not recently revascularised. Of these patients, 218
were randomised to and underwent angiography. All but one had CCS grading
recorded at baseline. We selected these 217 CECaT patients as IPD for our
analysis.
In our terminology, EUROPA is Study 1, CE-MARC is Study 2, CECaT is
Study 3, and symptomatic angina at baseline is x′. We denote by x′′ the vector
of covariates available from both CE-MARC and CECaT, and by x′′′ the vector
of covariates not available from CECaT (Table 2).
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Baseline characteristics (x) EUROPA CE-MARC CECaT
x′: Symptomatic angina (CCS grade II – IV) X X
x′′: Insignificant stenosis (negative angiography) X X
Years older than 65 X X X
Gender X X X
Systolic blood pressure (mm Hg) X X X
History of myocardial infarction X X X
Diabetes mellitus X X X
Smoking X X X
Obesity (body mass index over 30kg/m2) X X X
Family history of CHD X X X
Lipid lowering drug use X X X
x′′′: Nitrate use X X
Total cholesterol (mmol/L) X X
Creatinine clearance below 80 (ml/min) X X
History of TIA, PVD or CVA X X
Angiotensin converting enzyme (ACE) inhibitor use X X
Calcium antagonist use X X
Table 2: Baseline variables, their use in EUROPA and their availability in the
CE-MARC and CECaT data sets. (TIA: transient ischaemic attack. PVD:
peripheral vascular disease. CVA: cerebrovascular accident.)
Model selection
The strategy for model selection was to work up from the simplest model, ex-
amining data sources and assumptions until reaching a model adequately rep-
resenting our situation. The model in Figure 3 could not be used because the
CECaT data did not include some necessary covariates. The model in Figure 4
would require x′ ⊥⊥ x′′′ | (x′′, γ), which is doubtful because x′ is an indicator
for symptomatic angina and x′′′ includes an indicator for use of nitrates, which
are used to relieve and prevent angina.
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We could have taken the approach of either Figure 5 or Figure 6, which
would allow us to ignore x′′′ for CECaT patients. But these models would
both require us to choose auxiliary variables z such that we could assume
x′ ⊥⊥ x′′′ | (x′′, z, γ). Alternatively, we could handle unobserved covariates
in CECaT by specifying a joint conditional distribution for all variables in x′′′,
given x′′, and using the model in Figure 7.
We adapted the approach of Figure 7, avoiding the need to specify a joint
distribution for x′′′ by choosing to impute only nitrate use for CECaT patients.
Writing x′′′ = (x∗, x∗∗), where x∗ denotes the binary covariate for nitrate use
and x∗∗ denotes the vector of covariates to be ignored, we used the model in
Figure 8. The assumptions required were x′ ⊥⊥ x∗∗ | (x′′, x∗, γ) and x∗ ⊥⊥ x∗∗ |
(x′′, θ).
Figure 8: Selected model for updating β using the CE-MARC and CECaT
data sets. Variables included are y (time to first CV event), x∗ (nitrate use),
x∗∗ (total cholesterol, creatinine clearance below 80, TIA/PVD/CVA, ACE
inhibitor use, calcium antagonist use), x′ (symptomatic angina) and x′′ (as in
Table 2).
Implementation
Sampling methods provide a straightforward and efficient way to obtain an ap-
proximate posterior distribution for β. Specifically, we used MCMC methods in
the freely available OpenBUGS software.14 An example program is provided in
the online supplement to this paper.
Logistic regression models were assumed for the conditional distributions of
the unobserved covariates, p(x′ | x′′, x∗, γ) and p(x∗ | x′′, θ). Initial analysis
using vague normal priors, p(γ) and p(θ), led to very unstable Markov chains.
To overcome such problems, Gelman et al.19 proposed a default method to as-
sign weakly informative priors for logistic regression: shift each covariate by
subtracting its mean, divide each continuous covariate by twice its standard
deviation,20 then assign independent Cauchy distributions to each parameter
(centre 0, scale 2.5 for coefficients, scale 10 for intercept terms). These priors
were chosen to give preference to reasonable values for the regression coefficients
(around 50% prior probability of lying between -5 and 5).
We assigned priors p(γ) and p(θ) using reasoning similar to that of Gelman
et al. However, to avoid dependence of our priors on the CE-MARC and CE-
CaT data, we shifted and scaled our covariates using summaries from EUROPA.
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Also, since we would not anticipate large effect sizes in our context, and to avoid
known limitations of Cauchy priors,21 we assigned normal priors with the rec-
ommended scale parameters. These are less conservative than Cauchy priors,
giving each regression coefficient around 95% prior probability of lying between
-5 and 5.
Some events were censored at known times c(2)i because of non-CV death,
withdrawal or the end of follow-up. Assuming ignorable censoring, the cen-
sored event times y(2)i were sampled conditional on y(2)i > c(2)i. Implementing
this in OpenBUGS is straightforward.22 Also, some CE-MARC patients were
recorded at baseline to have suffered previous acute coronary syndrome, but
it was not specified whether this had been myocardial infarction or unstable
angina. Therefore the myocardial infarction covariate for these patients was
sampled from a Bernoulli distribution, informed by the ratio of myocardial in-
farction to unstable angina observed in the ENACT study.23
Model fit was checked graphically by comparing empirical data summaries to
their posterior predictive distributions and by calculating Bayesian p-values.15,24,25
For example, potential underestimation or overestimation of event rates was in-
vestigated by assessing censoring of predicted event times. At each iteration
of the Gibbs sampler, an event time was simulated for each CE-MARC patient
conditional on the sampled value of β. For each iteration, we calculated the
proportion pi of predicted events that would be censored (at either c(2)i or at
the final planned follow-up). We then compared a histogram of pi (which had
mean 90% and standard deviation 2%) to the actual proportion of censored
times in the data (93%). This suggested some overestimation of event rates,
with p-value P (pi > 93%) = 0.1. These checks were repeated in various sub-
sets of the CE-MARC sample and under different scenarios for censoring, each
producing similar results.
Results
The relevant input to the original cost-effectiveness model was a CV event rate
λ for a ‘base case’ patient with a given set of baseline characteristics x. This
rate was a deterministic function of β and x. For PSA, a rate λ was calculated
from each sampled β.
In our analysis, we had two such rates as model inputs: one for a base
case patient with significant stenosis (entering the model in either the FN or
TP state), and another for an otherwise identical patient with CHD but only
insignificant stenosis (entering the model in the TN state). Using our sampled
values of β, the approximate posterior distributions of these rates are plotted
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separately in Figure 9.
Figure 9: Histograms (left) showing posterior distributions of the rate of CV
events (λ) for base case patients with significant or insignificant stenosis.
Forest plot (right) showing the prior/posterior mean of each hazard ratio (eβi)
with 90% highest prior/posterior density (HPD) intervals.
By construction, the prior distribution of λ in Figure 9 for a patient with
significant stenosis was exactly the distribution obtained from EUROPA, as
used in the original CE-MARC cost-effectiveness analysis. The posterior was
very similar to this prior. This was because the update had little impact on
the hazard ratios eβ1 , . . . , eβ16 , or on eβ0 which had prior mean 0.018 (highest
prior density interval 0.008 to 0.028) and posterior mean 0.017 (highest poste-
rior density interval 0.008 to 0.026).
However, the posterior of λ for a patient with insignificant stenosis was
clearly different. On average, in the posterior, the event rate for a base case
patient with insignificant stenosis was around half that of an otherwise identical
patient with significant stenosis. Our posterior sample suggested around a 97%
probability of the event rate being lower (eβ17 < 1) in patients with insignificant
stenosis. The assumption made in the original analysis, that λ is the same in
all three initial states, is therefore unlikely to be true.
Despite this, conclusions from the updated cost-effectiveness analysis, using
the posterior distributions in Figure 9, were in agreement with those obtained
using only the prior information from EUROPA. The base case scenario we
considered was males, under 65, suffering from symptomatic angina and tak-
ing ACE inhibitors, who were otherwise average and without any other risk
factors listed in Table 2. Analysis using the EUROPA priors gave 55% proba-
bility of the MRI-CA strategy being cost-effective at willingness to pay £30,000
per QALY. Expected costs and QALYs of MRI-CA were £13,920 and 10.73
respectively. The updated analysis produced the same probability and simi-
lar expected QALYs (10.76), but lower expected costs (£13,825). For all eight
strategies compared, similar differences were seen between results of the two
analyses. For example, SPECT-CA had expected costs and QALYs £13,943
and 10.73 before the update, then £13,848 and 10.75 after.
Our update only had a notable effect on event rates in the TN state. The
proportion of patients entering TN would only vary between strategies through
very small differences in mortality due to misdiagnosed patients undergoing
unnecessary CA (Figure 1). Therefore comparisons between strategies would
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be affected very little, potentially explaining the agreement in our two analyses.
For example, although costs were lower in the updated analysis for all strategies,
incremental costs between strategies were similar in both analyses. Had our
update significantly affected event rates in the FN and TP states (for example,
if estimates from EUROPA were less precise or were in clear disagreement with
the observed data), then there might have been more impact on our conclusions
because the proportion of patients entering these states depends more heavily
on diagnostic accuracy of a strategy.
Discussion
We have presented a framework for updating decision model parameters based
on regression equations when the available data do not include all of the nec-
essary covariates. These methods are flexible and usually easy to implement
in freely available sampling-based software. The graphical modelling approach
encourages explicit statement of any independence assumptions. Using our mo-
tivating example, we demonstrated how these methods can be extended to more
specific problems when necessary.
Our example had one unobserved covariate in each study. In other situa-
tions, it might be necessary to handle multiple unobserved covariates in each
study. We would ideally specify multivariate distributions for these covariates.
For example, for multiple unobserved binary covariates we might use a multi-
nomial regression model. Also, for clarity, we demonstrated our methods using
a complete case analysis. Limitations of such analyses are well known16 and
Bayesian methods for dealing with intermittently missing data are described
elsewhere.4,5 Use of these methods in combination with our proposed methods
might require additional independence assumptions, or specification of multi-
variate distributions simultaneously describing unobserved and intermittently
missing covariates.
We did not address the issue of how much weight should be given to the
prior information. EUROPA was a large trial and produced very precise pa-
rameter estimates. However, the timing and setting of EUROPA (424 centres
in EUROPE, 1997 to 2000) were very different to CE-MARC (a single centre
in England, 2006 to 2009). Therefore the priors from EUROPA may have dom-
inated to an unacceptable degree, which might explain why our model checks
suggested some overestimation of event rates. A related issue is inconsistency
between data sources. Trials have been criticised for their selection bias, with
trial results often applied uncritically to a target population, despite differences
in patient characteristics and disease severity.26 Further work could investigate
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how existing models for cost-effectiveness could be updated to target popu-
lations within this framework, with appropriate weighting of trial and target
population data.
Imputation of unobserved covariates across multiple studies was inspired by
methods from epidemiology.27–29 However, our methods have a different pur-
pose. For example, Jackson et al.27 fit one regression model using two data sets,
each containing the same response variable but different subsets of the desired
covariates. This was done to address confounding that might have arisen if the
analysis was performed on a single data set, omitting unobserved covariates. In
contrast, we considered a previously estimated model and introduced additional
data to make an otherwise hopeless update possible, not to address confound-
ing. We are unaware of any previous applications of similar methods in health
economics.
In summary, we have presented methods to update an existing model us-
ing a data set with an incomplete set of covariates. However, these methods
should not be applied blindly. Priors should be carefully chosen, independence
assumptions should be justified, and discrepancies between model predictions
and observed data should be investigated.
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